A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Study summary

The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedLY3475070 and Pembrolizumab

The study team can explain what participation involves.

Who it may be forAdvanced Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 5, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?12 U.S. locations

Locations may change over time.

Who runs it?Eli Lilly and Company

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Eli Lilly and Company
Interventions being studied: Drug: LY3475070; Drug: Pembrolizumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer
Participants must have stopped other forms of treatment for the cancer
In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study
Participants must not be pregnant, and must agree to use birth control
Participants must have progressed through or be intolerant to therapies with known clinical benefit

Reasons someone may not be able to joinExclusion criteria

Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids
Participant must not have cancer that has spread to the brain
Participant must not have received a vaccine within the last 30 days
Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery
Participant must not have an infection that is currently being treated

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Sarah Cannon Research Institute at HealthOneDenver, Colorado
Florida Cancer Specialists ORLANDO/DDULake Mary, Florida
START MidwestGrand Rapids, Michigan
Washington University Medical SchoolSt Louis, Missouri
Cleveland Clinic FoundationCleveland, Ohio
Sarah Cannon Research Institute SCRINashville, Tennessee
University of Texas MD Anderson Cancer CenterHouston, Texas
Peter MacCallum Cancer CentreMelbourne, Victoria
Addenbrookes HospitalCambridge, Cambridgeshire
Beatson West of Scotland Cancer CenterGlasgow, Scotland
Christie NHS Foundation TrustManchester
Royal Marsden NHS TrustSutton

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 5, 2024. Always confirm current availability with the study team.

View original record ↗